Insulin lispro/Insulin glargine

赖脯胰岛素/甘精胰岛素

Report date: 2024/06/03 15:15:41

Base Information

Drug NameInsulin lispro/Insulin glargine
Drug Alias Name甘精胰岛素/赖脯胰岛素Insulin glargine+Insulin lisproInsulin lispro+Insulin glargine甘精胰岛素+赖脯胰岛素赖脯胰岛素+甘精胰岛素 +[13] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyMainland China
CombinationsYes Insulin lisproInsulin glargine
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAdocia
China Registration ClassN/A

Develop Information

Active CompaniesAdociaTonghua Dongbao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A